Newsbenzinga
NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…